Chris Rivard

1.2k total citations · 1 hit paper
21 papers, 660 citations indexed

About

Chris Rivard is a scholar working on Pulmonary and Respiratory Medicine, Nephrology and Oncology. According to data from OpenAlex, Chris Rivard has authored 21 papers receiving a total of 660 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 6 papers in Nephrology and 6 papers in Oncology. Recurrent topics in Chris Rivard's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (4 papers) and Liver Disease Diagnosis and Treatment (3 papers). Chris Rivard is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (4 papers) and Liver Disease Diagnosis and Treatment (3 papers). Chris Rivard collaborates with scholars based in United States, New Zealand and China. Chris Rivard's co-authors include Richard J. Johnson, Miguel A. Lanaspa, Thomas Jensen, Yalçın Solak, Takahiko Nakagawa, Mehmet Kanbay, Carlos A. Roncal-Jiménez, MyPhuong T. Le, Takuji Ishimoto and Michiko Shimada and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Chris Rivard

21 papers receiving 649 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Uric acid in metabolic syndrome: From an innocent bystander to a central player

2015 293 citations Mehmet Kanbay, Thomas Jensen et al. European Journal of Internal Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chris Rivard United States	11	322	175	151	142	141	21	660
Julia Lepenies Germany	12	295 0.9×	75 0.4×	187 1.2×	172 1.2×	110 0.8×	16	754
Giuseppe Palmiero Italy	14	231 0.7×	95 0.5×	172 1.1×	103 0.7×	41 0.3×	54	802
Qingwen Wang China	13	363 1.1×	61 0.3×	125 0.8×	61 0.4×	77 0.5×	28	622
Anurag Singh United Kingdom	9	428 1.3×	79 0.5×	203 1.3×	52 0.4×	56 0.4×	18	906
Faysal Gök Türkiye	18	189 0.6×	109 0.6×	289 1.9×	67 0.5×	63 0.4×	70	934
Jacek Zachwieja Poland	15	345 1.1×	69 0.4×	272 1.8×	49 0.3×	65 0.5×	85	870
Hideki Yamaya Japan	12	158 0.5×	91 0.5×	68 0.5×	63 0.4×	97 0.7×	28	625
Stine E. Nielsen Denmark	12	494 1.5×	92 0.5×	150 1.0×	204 1.4×	60 0.4×	16	903
Sanae Watanabe Japan	16	105 0.3×	100 0.6×	170 1.1×	120 0.8×	40 0.3×	30	825
Katherine Bennett Canada	7	267 0.8×	88 0.5×	254 1.7×	121 0.9×	48 0.3×	10	950

Countries citing papers authored by Chris Rivard

Since Specialization

Citations

This map shows the geographic impact of Chris Rivard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Rivard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Rivard more than expected).

Fields of papers citing papers by Chris Rivard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Rivard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Rivard. The network helps show where Chris Rivard may publish in the future.

Co-authorship network of co-authors of Chris Rivard

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Rivard. A scholar is included among the top collaborators of Chris Rivard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Rivard. Chris Rivard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yu, Hui, Leonid Churilov, Gareth Rivalland, et al.. (2021). NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort. Clinical Lung Cancer. 23(2). e90–e98. 6 indexed citations

Hirsch, Fred R., Mary W. Redman, James Moon, et al.. (2021). EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. Clinical Lung Cancer. 23(1). 60–71. 11 indexed citations

Tsakonas, Georgios, Johan Botling, Patrick Micke, et al.. (2019). c-MET as a biomarker in patients with surgically resected non-small cell lung cancer. Lung Cancer. 133. 69–74. 24 indexed citations

Tirunagaru, Vijaya G., Adriana Estrada‐Bernal, Hui Yu, et al.. (2019). Abstract 2202: Tarloxotinib exhibits potent activity in NRG1 fusion and rearranged cancers. 2202–2202. 3 indexed citations

Tirunagaru, Vijaya G., Adriana Estrada‐Bernal, Hui Yu, et al.. (2019). Abstract 2202: Tarloxotinib exhibits potent activity in NRG1 fusion and rearranged cancers. Cancer Research. 79(13_Supplement). 2202–2202. 6 indexed citations

Yu, Hui, Shevan Silva, Adriana Estrada‐Bernal, et al.. (2019). Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers. Cancer Research. 79(13_Supplement). 4025–4025. 3 indexed citations

Yu, Hui, Shevan Silva, Adriana Estrada‐Bernal, et al.. (2019). Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers. 4025–4025. 1 indexed citations

Wang, Yan, Zhen Qin, Quanren Wang, et al.. (2018). Comparison the anti-tumor effect of pyrotinib, afatinb and T-DM1 in lung cancer organoids and PDX models with HER2 mutation.. Journal of Clinical Oncology. 36(15_suppl). e24281–e24281. 5 indexed citations

He, Yayi, Yan Wang, Caicun Zhou, et al.. (2016). Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases. OncoTargets and Therapy. 9. 2409–2409. 4 indexed citations

10.

He, Yayi, Hui Yu, Rafał Dziadziuszko, et al.. (2016). LAG 3/MHC 2 and PD 1/PD L1 expression in non-small cell lung cancer patients.. Journal of Clinical Oncology. 34(15_suppl). 3039–3039. 1 indexed citations

11.

He, Yayi, Yan Wang, Theresa A. Boyle, et al.. (2016). Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma. Medical Science Monitor. 22. 276–283. 20 indexed citations

12.

Kanbay, Mehmet, Thomas Jensen, Yalçın Solak, et al.. (2015). Uric acid in metabolic syndrome: From an innocent bystander to a central player. European Journal of Internal Medicine. 29. 3–8. 293 indexed citations breakdown →

13.

Sullivan, Jillian S., Zhaoxing Pan, Chris Rivard, et al.. (2014). Oral fructose absorption in obese children with non‐alcoholic fatty liver disease. Pediatric Obesity. 10(3). 188–195. 51 indexed citations

14.

Johnson, Rabia, Miguel A. Lanaspa, Laura Gabriela Sánchez‐Lozada, et al.. (2014). Fat storage syndrome in Pacific peoples: a combination of environment and genetics?. PubMed. 20(1). 11–6. 11 indexed citations

15.

D’Arcangelo, M., Odd Terje Brustugun, Yang Xiao, et al.. (2014). Prevalence and Prognostic Significance of Sodium-Dependent Phosphate Transporter 2B (Napi2B) Protein Expression in Non-Small Cell Lung Cancer (Nsclc). Annals of Oncology. 25. iv66–iv66. 11 indexed citations

16.

Ishimoto, Takuji, Michiko Shimada, Tomoki Kosugi, et al.. (2012). Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice. Nephrology Dialysis Transplantation. 28(6). 1439–1446. 43 indexed citations

17.

Johnson, Richard J., Chris Rivard, Miguel A. Lanaspa, et al.. (2012). Fructokinase, Fructans, Intestinal Permeability, and Metabolic Syndrome: An Equine Connection?. Journal of Equine Veterinary Science. 33(2). 120–126. 45 indexed citations

18.

Huskey, Janna L., Chris Rivard, Han Myint, et al.. (2012). Minimal change disease in graft versus host disease: a podocyte response to the graft?. Clinical Nephrology. 80(12). 469–473. 5 indexed citations

19.

Altmann, Christopher, Ana Andrés-Hernando, Rachel H. McMahan, et al.. (2011). Macrophages mediate lung inflammation in a mouse model of ischemic acute kidney injury. American Journal of Physiology-Renal Physiology. 302(4). F421–F432. 43 indexed citations

20.

Shimada, Michiko, Carlos E. Araya, Chris Rivard, et al.. (2010). Minimal change disease: a “two-hit” podocyte immune disorder?. Pediatric Nephrology. 26(4). 645–649. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact